GIỚI THIỆU VỀ TẬP NÀY
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with Peter Kolchinsky, PhD, Founder and Managing Partner of RA Capital Management, to discuss if the U.S. market-based approach to pricing novel prescription medicines could result in paying more than they are worth and if companies and company builders should use health economic modeling to support their value propositions.
Tiếng Anh
Hoa Kỳ
BẢN CHÉP ÂM THANH 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
TÌM KIẾM CÁC TẬP TRƯỚC
Tìm kiếm các tập trước của Perspectives by the Leerink Center for Pharmacoeconomics.
CÁC TẬP KHÁC TRONG PODCAST NÀY
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech, to discuss the impact of the Inflation Reduction Act on cancer drug development and a middle ground between a market-based approach and a government-b…
Diane Vieira, Head of Marketing & Communications at Leerink Partners, interviews Melanie Whittington, PhD, Head of the Leerink Center of Pharmacoeconomics (CPE), to discuss the one-year anniversary of CPE and everything they thought they knew but actually didn’t.
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews James Chambers, PhD, MPharm, Professor of Medicine in the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, to dig into specialty drug coverage and what it might look like in 2026.
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a path forward for broader, faster adoption across larger patient populations. Given the slow adoption cur…
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O'Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without bus…
Tuyên bố miễn trừ trách nhiệm: Podcast và tác phẩm nghệ thuật được nhúng trên trang này là của The Leerink Center for Pharmacoeconomics, là tài sản của chủ sở hữu và không được liên kết hoặc xác nhận bởi Listen Notes, Inc.
CHỈNH SỬA
Cảm ơn bạn đã giúp cơ sở dữ liệu podcast luôn cập nhật.
